{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041549","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.423698+00:00","generated_at":"2026-06-04T04:21:28.692057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Brainstorm Cell reports FY2023 net loss of $17.2M; cash drops to $1.45M; awaits FDA SPA","bullets":["Net loss $17.2M ($0.40/share) vs $24.3M ($0.66) in 2022; no revenue (pre-revenue biotech).","Cash and equivalents $1.45M at Dec 31, 2023, down from $3M in 2022; raises going-concern risk.","R&D expenses fell to $10.8M from $14M; headcount reduced ~30% in October 2023 strategic realignment.","Submitted SPA request to FDA in Feb 2024 for Phase 3b trial of NurOwn in ALS; awaiting 45-day review.","Withdrew BLA for NurOwn in Oct 2023 after FDA advisory committee voted against effectiveness evidence."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041549","json":"https://secwatch.observer/filing/0001104659-24-041549.json","markdown":"https://secwatch.observer/filing/0001104659-24-041549.md","text":"https://secwatch.observer/filing/0001104659-24-041549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924041549/0001104659-24-041549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924041549/tm2410297d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:21:28.692057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05bc3f968badfc108f27664a10bfc76ecebf380e","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported the year ended December 31, 2023 results: net income $17.2 million, EPS $0.40.","evidence_excerpt":"On April 1, 2024, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924041549/0001104659-24-041549-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$17.2 million"},{"label":"EPS","value":"$0.40"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}